Background {#Sec1}
==========

Total mesorectal excision (TME) has substantially contributed to improvement in loco-regional recurrence rates and survival for patients with rectal cancer \[[@CR1]\]. In addition, benefits in local disease control, toxicity, and sphincter preservation have been achieved by preoperative chemoradiation therapy (CRT), which is the currently standard management for locally advanced rectal cancer (LARC) \[[@CR2]\]. Therefore, the focus on improving outcomes has changed from lowering the local recurrence rate to reducing distant recurrence, which still occurs in approximately one-third of patients treated surgically with curative intent \[[@CR3]\]. In colon cancer, adjuvant single agent 5-fluorouracil (5-FU) chemotherapy has led to an increase in overall survival (OS), of approximately 10% for patients with American Joint Committee on Cancer (AJCC) stage III disease and a further 5% by adding oxaliplatin \[[@CR4]--[@CR7]\]. Based on this background, many researchers have tried to extrapolate the benefits of adjuvant chemotherapy (AC) for colon cancer to the treatment of rectal cancer. Even if a surgical specimen obtained from radical resection reveals a complete response without any viable tumor cells, the patient is expected to complete 4--6 months of AC based on their clinical stage, which was estimated before preoperative treatment \[[@CR8], [@CR9]\].

However, the efficacy of AC in patients with LARC after preoperative CRT and TME has not been documented to the same extent, and the clinical benefit remains controversial \[[@CR10]\]. In this context, international and national treatment guidelines differ in their recommendations regarding to AC in LARC \[[@CR11], [@CR12]\]. The initial results of the EORTC 22921 trial indicated that only patients with a good prognosis (ypT0--2) benefited from AC \[[@CR13]\]. However, the final results indicated that adjuvant 5-FU-based chemotherapy after preoperative radiotherapy with or without chemotherapy did not improve disease-free survival (DFS) and OS in all patients, including patients with a good prognosis (ypT0--2) \[[@CR14]\]. In contrast, patients with a high risk for recurrence (yp stage III) benefited from adding oxaliplatin to 5-FU as AC after preoperative 5-FU-based CRT and TME \[[@CR15]\]. With these heterogeneous results about the role of AC, we aimed to investigate the value of AC with fluoropyrimidine mono-therapy after preoperative CRT and TME in ypT0-3N0 patients, who are considered to have a good prognosis.

Methods {#Sec2}
=======

Patients and pretreatment evaluation {#Sec3}
------------------------------------

Patients who were diagnosed with LARC, were treated with preoperative CRT and TME, and had ypT0-3N0M0 as the final pathologic diagnosis at Yonsei Cancer Center between January 2001 and December 2013 were included. Patients who underwent trans-anal excision and received AC with oxaliplatin were excluded.

Pathologic diagnosis by biopsy was performed for all patients before treatment. To determine the clinical stage, the pretreatment evaluation involved a physical examination including a digital rectal examination; carcinoembryonic antigen (CEA); abdomino-pelvic computed tomography (CT); chest CT; rectal magnetic resonance imaging; and positron emission tomography (PET)-CT, when there was a suspicion of distant metastasis. Clinical and pathologic staging were determined according to the AJCC TNM staging system, 7th edition \[[@CR16]\].

Treatment and follow-up {#Sec4}
-----------------------

Preoperative radiation therapy involved a total of 45--50.4 Gray radiation delivered in 25--28 fractions to the tumor and drained lymph node. Preoperative chemotherapy with concurrent radiotherapy included 5-FU administered as a 400-mg/m^2^ bolus and leucovorin administered as a 20-mg/m^2^ bolus during the first and last weeks of radiotherapy or 850-mg/m^2^ capecitabine twice a day during the entire period of radiotherapy. Surgical resection with TME was performed 4--8 weeks after completion of the CRT.

AC consisted of 5-FU administered as a 400-mg/m^2^ bolus and leucovorin administered as a 20-mg/m^2^ bolus on days 1--5 every 28 days for 4 cycles or 1250-mg/m^2^ capecitabine twice a day on days 1--14 every 21 days for 5 cycles. The chemotherapeutic agents were the same as those used in the preoperative CRT.

Patients were followed at 3-month intervals during the first 2 years after surgery, at 6-month intervals during the next 3 years, and annually thereafter. At each visit during the regular follow-ups, a serum CEA assay was performed. Abdomino-pelvic CT was performed at 6-month intervals, chest CT was performed at 12-month intervals, and both were performed annually after 5 years. If recurrence was suspected, the follow-up examinations included a clinical evaluation, physical examination, serum CEA assay, chest CT, abdomino-pelvic CT, colonoscopy, and PET, as appropriate. Recurrence was determined using clinical and radiological examinations or histological assessment.

Statistical analysis {#Sec5}
--------------------

To evaluate the benefit of AC for patients with LARC treated with preoperative CRT and TME, we compared survival between the patients with AC (adjuvant group) and those without AC (observation group). To reduce the effect of treatment-selection bias and simulate the effects of randomization, propensity score matching was used. Propensity scores were estimated using a logistic regression model based on age, sex, tumor location, histologic differentiation, pretreatment CEA level, surgical procedure, pathologic stage, number of retrieved lymph nodes, lymphovascular or perineural invasion, and margin involvement. One-to-one matching without replacement was performed using a 0.2 caliper width, and the resulting score-matched pairs were used in subsequent analyses, as indicated.

The statistical significance of differences was assessed using the Chi-square test for categorical variables and Wilcoxon rank sum test for continuous variables unless specifically mentioned. OS was defined as the time from the date of surgery to the date of death from any cause. DFS was defined as the time from the date of surgery to the detection of recurrent disease or death, whichever occurred first. Survival curves were generated using the Kaplan-Meier method, and survival was compared using Cox regression analysis. To identify the subpopulations that benefited from AC, subgroup analysis was performed by stratifying patients according to patient demographics and tumor characteristics in the entire sample as well as the propensity score-matched cohort. All analyses were conducted with the statistical program R (R Foundation for Statistical Computing, Vienna, Austria). All *P*-values are two-sided, and *P* \< 0.05 was used to denote statistical significance.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

Of the 365 patients with LARC (radiological T3--4 or N+) who underwent neoadjuvant CRT with 5-FU or capecitabine followed by TME, 5 patients who underwent a trans-anal excision and 21 patients who sequentially received AC with oxaliplatin were excluded (Fig. [1](#Fig1){ref-type="fig"}). Therefore, the analyses included 339 patients with ypT0-3N0 primary adenocarcinoma of the rectum.Fig. 1Flowchart of the study population

The baseline characteristics of all patients are presented in Table [1](#Tab1){ref-type="table"}. The median number of harvested lymph nodes was 12 (interquartile range \[IQR\], 9--17), and total pathologic complete remission (ypT0N0) was achieved in 90 patients (26.5%). Of the 399 patients, 87 patients (25.7%) did not receive AC. Compared with patients who did not receive AC, patients who received AC were younger, had a more advanced pathologic stage, and experienced a poor response to preoperative CRT. Other clinicopathologic characteristics were similar between the adjuvant and observation groups.Table 1Baseline characteristics of patients with ypT0-3N0 rectal cancerBefore matchingAfter matchingOverall *n* = 339 (%)No AC *n* = 87 (%)AC *n* = 252 (%)*p-*valueNo AC *n* = 87 (%)AC *n* = 87 (%)*p-*valueMedian age (range), years59.6 (27.2--85.7)65.9 (36.0--85.7)58.3 (27.2--84.6)\<0.00165.9 (36.0--85.7)63.7 (39.1--84.6)0.251Sex0.7520.602 Male246 (72.6)62 (71.3)184 (73.0)62 (71.3)59 (67.8) Female93 (27.4)25 (28.7)68 (27.0)25 (28.7)28 (32.2)Distance from AV (cm)0.342 ≥ 10.035 (10.3)8 (9.2)27 (10.7)8 (9.2)9 (10.3) 5.0--9.9140 (41.3)33 (37.9)107 (42.5)33 (37.9)40 (46.0) \< 5.0164 (48.4)46 (52.9)118 (46.8)46 (52.9)38 (43.7)Differentiation0.1760.300 Well70 (20.6)17 (19.5)53 (21.0)17 (19.5)20 (23.0) Moderate248 (73.2)61 (70.1)187 (74.2)61 (70.1)62 (71.3) Poor, mucinous21 (6.2)9 (10.3)12 (4.8)9 (10.3)5 (5.7)Pretreatment CEA (ng/mL)0.6210.413 \< 5214 (63.1)53 (60.9)161 (63.9)53 (60.9)58 (66.7) ≥ 5125 (36.9)34 (39.1)91 (36.1)34 (39.1)29 (33.3)Surgical procedure0.5730.350 LAR298 (87.9)75 (86.2)232 (88.5)75 (86.2)79 (90.8) APR41 (12.1)12 (13.8)29 (11.5)12 (13.8)8 (9.2)Stage\<0.0010.383 ypT090 (26.5)40 (46.0)50 (19.8)40 (46.0)37 (42.5) ypT119 (5.6)6 (6.9)13 (5.2)6 (6.9)4 (4.6) ypT296 (28.3)25 (28.7)71 (28.2)25 (28.7)26 (29.9) ypT3134 (39.5)16 (18.4)118 (46.8)16 (18.4)20 (23.0)LN dissected0.1460.538 \< 12145 (42.8)43 (49.4)102 (40.5)43 (49.4)39 (44.8) ≥ 12194 (57.2)44 (50.6)150 (59.5)44 (50.6)48 (55.2)LVI/PNI0.8120.657 Negative278 (82.0)71 (81.6)207 (82.1)71 (81.6)80 (92.0) Positive15 (4.4)3 (3.4)12 (4.8)3 (3.5)2 (2.3) NA46 (13.6)13 (14.9)33 (13.1)13 (14.9)5 (5.8)Margin0.6771.000 Negative329 (97.1)85 (97.7)244 (96.8)85 (97.7)85 (97.7) Positive10 (2.9)2 (2.3)8 (3.2)2 (2.3)2 (2.3)Mandard regression grade\<0.0010.926 Grade 190 (26.5)40 (46.0)50 (19.8)40 (46.0)37 (42.5) Grade 290 (26.5)17 (19.5)73 (29.0)17 (19.5)22 (25.3) Grade 378 (23.0)11 (12.6)67 (26.6)11 (12.6)15 (17.2) Grade 436 (10.6)6 (6.9)30 (11.9)6 (6.9)8 (9.2) NA45 (13.3)13 (14.9)32 (12.7)13 (14.9)5 (5.8)*AC* adjuvant chemotherapy, *AV* anal verge, *CEA* carcinoembryonic antigen, *LAR* lower anterior resection, *APR* abdomino-perineal resection, *LN* lymph node, *LVI* lymphovascular invasion, *PNI* perineural invasion, *NA* not assessed

Oncologic outcomes {#Sec8}
------------------

The mean follow-up duration was 70.7 months (95% confidence interval, 65.9--75.5 months), and the duration was similar between the two groups (*P* = 0.650). Local recurrence and systemic recurrence occurred in 23 patients (6.8%) and 57 patients (16.8%), respectively. The lung was the most common site of distant metastasis (37 patients), followed by the liver (16 patients) and distant lymph nodes (7 patients). A total of 40 patients died, and 28 deaths occurred due to cancer progression. No treatment-related mortality was reported. In the multivariate Cox regression analysis, old age (\>70 years old), abdomino-perineal resection, advanced pathologic stage (ypT stage), lymphovascular or perineural invasion, and a positive resection margin were associated with inferior DFS. In addition, patients who were older, had an advanced pathologic stage, and had a positive resection margin showed poor OS in the multivariate analysis (Table [2](#Tab2){ref-type="table"}). However, there were no significant differences in DFS and OS based on AC (Fig. [2](#Fig2){ref-type="fig"}). The 5-year DFS were 78.0% in the observation group and 76.8% in the adjuvant group (hazard ratio \[HR\], 0.921; 95% confidence interval \[CI\], 0.562--1.507; *P* = 0.742). AC did not confer a benefit in terms of both local recurrence (HR, 1.583; 95% CI, 0.538--4.652; *P* = 0.404), and systemic recurrence (HR, 1.070; 95% CI, 0.585--1.956; *P* = 0.825). The 5-year OS were 91.6% in the observation group and 88.1% in the adjuvant group (HR, 0.835; 95% CI, 0.423--1.648; *P* = 0.603).Table 2Factors associated with disease-free survival and overall survival in the entire sample of patients with ypT0-3N0 rectal cancerDisease-free survivalOverall survivalUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR (95% CI)*p-*valueHR (95% CI)*p-*valueHR (95% CI)*p-*valueHR (95% CI)*p-*valueAge, years0.0020.0130.001\<0.001 \< 701111 ≥ 702.091 (1.299--3.366)1.944 (1.148--3.293)3.026 (1.584--5.780)3.606 (1.848--7.038)Sex0.2260.051 Female11 Male1.393 (0.814--2.384)2.549 (0.998--6.511)Distance from AV (cm)0.1220.302 ≥ 10.011 5.0--9.90.754 (0.340--1.674)0.683 (0.220--2.122) \< 5.01.256 (0.591--2.668)1.184 (0.407--3.443)Differentiation0.6460.327 Well11 Moderate1.045 (0.591--1.848)1.103 (0.480--2.536) Poor, mucinous1.493 (0.607--3.677)2.202 (0.692--7.010)Pretreatment CEA (ng/mL)0.0050.0570.088 \< 5111 ≥ 51.877 (1.207--2.918)1.628 (0.985--2.692)1.717 (0.923--3.196)Surgical procedure0.001\<0.0010.0080.059 LAR1111 APR2.492 (1.480--4.196)3.919 (1.996--7.697)2.538 (1.272--5.064)2.007 (0.974--4.135)Stage0.0050.0470.0070.007 ypT01111 ypT12.234 (0.688--7.256)1.876 (0.505--6.972)5.049 (1.018--25.046)4.853 (0.977--24.109) ypT22.317 (1.066--5.038)2.661 (1.193--5.936)1.872 (0.483--7.261)1.488 (0.379--5.842) ypT33.555 (1.732--7.295)2.917 (1.354--6.284)5.340 (1.612--17.684)4.742 (1.419--15.843)LN dissected0.1190.100 ≥ 1211 \< 121.421 (0.913--2.212)1.691 (0.904--3.166)LVI/PNI0.0050.0230.445 Negative111 Positive3.047 (1.391--6.678)2.606 (1.144--5.938)1.753 (0.415--7.401)Margin\<0.001\<0.001\<0.001\<0.001 Negative1111 Positive9.165 (4.653--18.050)6.348 (2.786--14.467)10.374 (4.546--23.673)7.933 (3.351--18.779)Mandard regression grade0.0040.050 Grade 111 Grade 22.503 (1.146--5.466)3.040 (0.823--11.230) Grade 33.324 (1.538--7.185)3.467 (0.938--12.809) Grade 44.434 (1.894--10.378)6.702 (1.731--25.946)Adjuvant chemotherapy0.7420.603 No11 Yes0.921 (0.562--1.507)0.835 (0.423--1.648)*HR* hazard ratio, *CI* confidence interval, *AV* anal verge, *CEA* carcinoembryonic antigen, *LAR* lower anterior resection, *APR* abdomino-perineal resection, *LN* lymph node, *LVI* lymphovascular invasion, *PNI* perineural invasion Fig. 2Kaplan-Meier survival plots of disease-free survival (**a**) and overall survival (**b**) based on the receipt of adjuvant chemotherapy in the entire sample

Propensity score-matched analysis {#Sec9}
---------------------------------

We conducted the propensity score-matched analysis because the patients treated with AC were younger, had a more advanced pathologic stage, and experienced a poor response to preoperative CRT and these parameters were independent poor prognostic factors in the Cox regression analysis. The propensity score matching resulted in 87 matched pairs, for a total of 174 patients. The patient characteristics were nearly balanced between the two groups (Table [1](#Tab1){ref-type="table"}). In the propensity score-matched cohort, there were also no significant differences in DFS and OS based on AC (Fig. [3](#Fig3){ref-type="fig"}). The 5-year DFS were 78.0% in the observation group and 73.7% in the adjuvant group (HR, 1.129; 95% CI, 0.626--2.035; *P* = 0.688). In addition, both local recurrence (HR, 2.206; 95% CI, 0.679--7.165; *P* = 0.188) and systemic recurrence (HR, 1.089; 95% CI, 0.526--2.258; *P* = 0.818) did not differ between the two groups. The 5-year OS were 91.6% in the observation group and 83.8% in the adjuvant group (HR, 1.200; 95% CI, 0.539--2.669; *P* = 0.655). In the propensity score-matched cohort, advanced pathologic stage and positive resection margin were associated with both inferior DFS and OS (Table [3](#Tab3){ref-type="table"}).Fig. 3Kaplan-Meier survival plots of disease-free survival (**a**) and overall survival (**b**) based on receipt of adjuvant chemotherapy in the propensity score-matched cohort Table 3Factors associated with disease-free survival and overall survival in the cohort of propensity score-matched patients with ypT0-3N0 rectal cancerDisease-free survivalOverall survivalUnivariate analysisMultivariate analysisUnivariate analysisMultivariate analysisHR (95% CI)*p-*valueHR (95% CI)*p-*valueHR (95% CI)*p-*valueHR (95% CI)*p-*valueAge, years0.0380.3820.0250.269 \< 701111 ≥ 701.873 (1.036--3.386)1.324 (0.706--2.483)2.513 (1.125--5.609)1.598 (0.695--3.673)Sex0.2200.0300.075 Female1111 Male1.553 (0.769--3.138)4.951 (1.167--21.005)3.782 (0.875--16.352)Distance from AV (cm)0.5110.416 ≥ 10.011 5.0--9.90.669 (0.256--1.745)0.510 (0.146--1.784) \< 5.00.956 (0.383--2.391)0.897 (0.281--2.862)Differentiation0.8960.464 Well11 Moderate0.842 (0.411--1.726)0.579 (0.233--1.439) Poor, mucinous0.871 (0.271--2.803)0.868 (0.220--3.432)Pretreatment CEA (ng/mL)0.0140.0390.348 \< 5111 ≥ 52.075 (1.156--3.727)1.912 (1.033--3.540)1.461 (0.662--3.226)Surgical procedure0.0390.3390.0330.225 LAR1111 APR2.133 (1.038--4.384)1.465 (0.670--3.206)2.615 (1.082--6.319)1.764 (0.705--4.411)Stage0.0030.0190.0020.007 ypT01111 ypT14.239 (1.299--13.831)3.461 (1.017--11.778)10.163 (2.033--50.817)6.894 (1.343--35.381) ypT22.388 (1.040--5.485)1.893 (0.808--4.434)2.243 (0.555--9.059)1.647 (0.387--7.005) ypT34.438 (1.963--10.032)3.517 (1.528--8.093)7.533 (2.114--26.848)5.782 (1.588--21.051)LN dissected0.7290.946 ≥ 1211 \< 120.901 (0.500--1.624)1.028 (0.467--2.259)LVI/PNI0.2940.591 Negative11 Positive2.149 (0.516--8.955)0.047 (0.000--3244.523)Margin\<0.0010.001\<0.0010.005 Negative1111 Positive8.956 (3.131--25.613)7.193 (2.234--23.156)10.375 (3.022--35.623)7.035 (1.806--27.404)Mandard regression grade0.0060.039 Grade 111 Grade 23.086 (1.319--7.222)5.268 (1.398--19.860) Grade 34.542 (1.880--10.970)4.113 (0.920--18.379) Grade 43.771 (1.263--11.261)8.159 (1.825--36.482)Adjuvant chemotherapy0.6880.655 No11 Yes1.129 (0.626--2.035)1.200 (0.539--2.669)*HR* hazard ratio, *CI* confidence interval, *AV* anal verge, *CEA* carcinoembryonic antigen, *LAR* lower anterior resection, *APR* abdomino-perineal resection, *LN* lymph node, *LVI* lymphovascular invasion, *PNI* perineural invasion

Subgroup analysis of the benefit of adjuvant chemotherapy {#Sec10}
---------------------------------------------------------

In general, AC was not associated with improved DFS and OS in the entire sample (Additional file [1](#MOESM1){ref-type="media"}: Table S1) or propensity score-matched patient cohort (Additional file [1](#MOESM1){ref-type="media"}: Table S2). However, AC was associated with poor DFS and OS among patients older than 70 years in both study subsets.

Discussion {#Sec11}
==========

In this study, we evaluated the outcomes of LARC for patients with ypT0-3N0, who are considered to have a relatively good prognosis, after preoperative CRT followed by TME, based on receipt of AC. AC did not improve survival in these patients. Because the analysis was conducted using data from a prospectively collected tumor registry, the adjuvant group was younger, had a more advanced pathologic stage, and experienced a poor response to preoperative CRT, compared with the observation group. Even after propensity score matching for these reasons, AC was also not associated with improved outcomes in terms of DFS and OS in the propensity score-matched cohort. We were also not able to identify any specific subpopulations that benefited from AC. These results were comparable with those from previous studies regarding the roles of AC in LARC after preoperative CRT or radiotherapy \[[@CR17]--[@CR20]\].

Before the era of preoperative CRT and TME, AC was associated with improved outcomes in rectal cancer \[[@CR10], [@CR21]\]. As loco-regional recurrence rates have recently decreased after the introduction of TME, reduction in distant metastases has become more important in rectal cancer treatment, similar to colon cancer. In addition, substantial improvements have been achieved recently in the management of rectal cancer after the introduction of preoperative CRT and TME. However, the long-term results of the EORTC 22921 \[[@CR14]\], CHRONICLE \[[@CR22]\], I-CNR-RT \[[@CR23]\], PROCTOR/SCRIPT \[[@CR3]\], and QUASAR trials \[[@CR24]\] are controversial regarding the benefits of AC in patients with LARC after preoperative CRT or radiotherapy followed by surgery. Although the rationale for AC after preoperative CRT was largely extrapolated from the results obtained with colon cancer, the clinical benefit of AC in rectal cancer needs to be validated, considering the different treatment modalities, recurrence patterns, and tumor biology \[[@CR25], [@CR26]\]. No conclusive evidence favoring AC in LARC after preoperative CRT and TME currently exists \[[@CR27]\].

For colon cancer, the benefit of AC has been clearly demonstrated for patients with stage III disease in multiple clinical trials and meta-analyses \[[@CR4]--[@CR7]\]. However, the benefit of AC in stage II colon cancers is less certain \[[@CR28], [@CR29]\]. For patients with stage II T4 colon cancer, AC was associated with improved survival \[[@CR30]\]. Therefore, we evaluated whether AC is needed in patients with LARC with ypT0-3N0 after preoperative CRT as well as the subgroup(s) that benefit from AC. However, AC did not appear to benefit any specific subgroup.

There are several possible reasons for a lack of clinical benefit from AC in patients with LARC and ypT0-3N0 after preoperative CRT and TME. First, AC is effective for patients who have a poor prognosis, such as those with stage III or T4 \[[@CR30]\]. According to the ADORE trial, which examined the role of oxaliplatin, fluorouracil, and leucovorin as AC for LARC, survival was improved with AC in patients with postoperative pathological stage III disease but not in patients with stage II disease \[[@CR15]\]. Second, there are embryological, anatomical, and physiological differences between colon and rectal cancers. Miscosatellite instability and *BRAF* mutation are important prognostic factors but are detected less often in rectal cancer than in colon cancer. A meta-analysis by Breugom et al. suggested that AC might benefit patients with a tumor located 10--15 cm from the anal verge \[[@CR31]\], and theoretically, a tumor arising above the peritoneal reflection is more likely to undergo distant spread \[[@CR32]\]. Last, the lack of benefit with AC might be attributed to poor compliance. Only 42.9% of participants in the EORTC 22921 trial \[[@CR13]\], 43% of participants in the CHRONICLE trial \[[@CR22]\], and 55% of the participants who received 3--6 courses of AC in the I-CNR-RT trial \[[@CR23]\] benefited from AC.

The researchers of the QUASAR trial identified the patient subgroups that were more likely to benefit from AC: \<70 years old, receipt of chemotherapy every 4 weeks, and \<6 weeks from surgery to AC \[[@CR24]\]. However, we did not identify a subgroup that benefited from AC in the current study, although old age was associated with worse prognosis with AC. Therefore, routine use of AC should be evaluated carefully, considering not only the patient characteristics, such as age and comorbidities, but also tumor characteristics, such as distance from the anal verge and the optimal chemotherapy regimen and duration.

This study has certain limitations. First, the analysis was based on data that were prospectively collected in a tumor registry. Therefore, the baseline characteristics differed, although we corrected this using propensity score-matched analysis. In addition, immortal time bias, caused by a period of time during which events cannot occur \[[@CR33]\], could act as a confounding factor. However, we found no definite differences in early recurrence or death as well as DFS and OS at different cut-off times after surgery between the adjuvant and observation groups in this study (Additional file [1](#MOESM1){ref-type="media"}: Tables S3 and S4). Also, this bias has clearly not affected the conclusion, because immortal time bias would tend to favor the adjuvant chemotherapy arm if present. Second, this study was conducted with a relatively small sample size, thus underpowered to ascertain the effect of adjuvant chemotherapy. However, the effect size found in the cohort of propensity-matched patients was 1.129 (HF for DFS), which is the opposite direction of the benefit from adjuvant chemotherapy as well as seems to be clinically irrelevant. Furthermore, statistical power for detecting such HR is less than 10%, which means that a huge sample size is needed to show statistical significance. Third, the results were derived from a single tertiary center, potentially lacking the external validation.

Conclusions {#Sec12}
===========

In summary, LARC patients with ypT0-3N0 did not benefit from AC after preoperative CRT and TME, which supports the findings of previous studies investigating the role of AC after preoperative CRT and TME and the conclusions of meta-analyses. However, there are conflicting results about the use of AC from many studies with diverse patient populations. Based on this context, a more intensive investigation is needed to evaluate the potential advantages and drawbacks of AC in the era of preoperative CRT and TME. Moreover, future studies should focus on identifying patient subpopulations that benefit from AC.

Additional file {#Sec13}
===============

Additional file 1: Table S1.Effect of adjuvant chemotherapy on disease-free survival and overall survival by patient demographics and tumor characteristics in the entire sample of patients. **Table S2.** Effect of adjuvant chemotherapy on disease-free survival and overall survival by patient demographics and tumor characteristics in the cohort of propensity score-matched patients. **Table S3.** Recurrence or death events at different times after surgery. Comparisons were done by Fisher's exact test. **Table S4.** Effect of adjuvant chemotherapy on disease-free survival and overall survival by restricting analysis to patients who remained event-free at different times after surgery. (DOCX 30 kb)
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